1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Theravance ends ADHD program for TD-9855

 
• By Mandy Jackson

Theravance CEO Rick Winningham said during a presentation at the Credit Suisse Annual Health Care Conference in Scottsdale, Arizona on 13 November that the company will discontinue development of TD-9855 in the treatment of attention-deficit/hyperactivity disorder (ADHD), because the drug did not meet the primary efficacy endpoint in a placebo-controlled Phase II clinical trial.

Theravance CEO Rick Winningham said during a presentation at the Credit Suisse Annual Health Care Conference in Scottsdale, Arizona on 13 November that the company will discontinue development of TD-9855 in the treatment of attention-deficit/hyperactivity disorder (ADHD), because the drug did not meet the primary efficacy endpoint in a placebo-controlled Phase II clinical trial.

South San Francisco-based Theravance reported Mr Winningham's comments on TD-9855 disclosure in a US Securities and Exchange Commission (SEC) filing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By Joseph Haas

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare

 
• By Andrew McConaghie

Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?